Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Research and Development

- PMLiVE

Circassia exits allergy R&D after placebo effect strikes again

Abandons phase IIb trial of house dust mite allergy candidate

- PMLiVE

Ipsen appoints new executive vp and president, primary care

Benoit Hennion will also join the executive leadership team

UK flag

ABPI delivers wish-list to Hammond ahead of spring budget

Pharma industry has three key requests

- PMLiVE

Ipsen boosts specialty care and R&D leadership teams

Harout Semerjian and Dr Sotirios Stergiopoulos join

Actelion HQ Switzerland

J&J agrees $30bn deal to acquire Actelion

Swiss biotech to retain control of early-stage pipeline as J&J takes minority stake in R&D spin-out

UK flag

Life sciences to play key role in UK’s post-Brexit strategy

Prime minister unveils plans to boost jobs, growth and commercialise country’s science base

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

- PMLiVE

Ipsen’s chief scientific officer steps down

Dr Claude Bertrand will be replaced ad interim by Alexandre Lebeaut

- PMLiVE

The future of biotech

What impact will the sector, and its R&D performance, have on pharma?

- PMLiVE

Ipsen buys cancer business from stripped down Merrimack

Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval

Bristol-Myers Squibb (BMS) building

BMS restructures US R&D operations

Unveils site closures and build plans as firm focuses pipeline around three US hubs

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links